Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Aug 15;13(8):e0007647.
doi: 10.1371/journal.pntd.0007647. eCollection 2019 Aug.

Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease

Samanta Moroni  1 , Maria Elena Marson  2   3 , Guillermo Moscatelli  1   4 , Guido Mastrantonio  2   3 , Margarita Bisio  1   4 , Nicolas Gonzalez  1 , Griselda Ballering  1 , Jaime Altcheh  1   4 , Facundo García-Bournissen  1   4
Affiliations
Clinical Trial

Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease

Samanta Moroni et al. PLoS Negl Trop Dis. .

Abstract

Background: Treatment with nifurtimox (NF) for Chagas disease is discouraged during breast-feeding because no information on NF transfer into breast milk is available. NF is safe and effective for paediatric and adult Chagas disease. We evaluated the degree of NF transfer into breast milk in lactating women with Chagas disease.

Patients and methods: Prospective study of a cohort of lactating women with Chagas disease. Patients were treated with NF for 1 month. NF was measured in plasma and milk by high performance liquid chromatography (HPLC). Breastfed infants were evaluated at admission, 7th and 30th day of treatment (and monthly thereafter, for 6 months).

Results: Lactating women with chronic Chagas disease (N = 10) were enrolled (median age 28 years, range 17-36). Median NF dose was 9.75 mg/kg/day three times a day (TID). Six mothers had mild adverse drug reactions (ADRs), but no ADRs were observed in any of the breastfed infants. No interruption of breastfeeding was observed. Median NF concentrations were 2.15 mg/L (Inter quartil range (IQR) 1.32-4.55) in milk and 0.30 mg/L (IQR 0.20-0.95) in plasma. Median NF milk/plasma ratio was 16 (range 8.75-30.25). Median relative infant NF dose (assuming a daily breastmilk intake of 150 mL/kg/day) was 6.7% of the maternal dose/kg/day (IQR 2.35-7.19%).

Conclusions: The low concentrations of NF in breast milk and the normal clinical evaluation of the breastfed babies imply that maternal NF treatment for Chagas disease during breastfeeding is unlikely to lead to clinically relevant exposures in the breastfed infants.

Trial registration: Clinical trial registry name and registration number: ClinicalTrials.gov NCT01744405.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Barry MA, Weatherhead JE. Childhood Parasitic Infections Endemic to the United States Chagas Intestinal protozoa Leishmania Childhood Toxoplasma Toxocara. 2013;60:471–485. 10.1016/j.pcl.2012.12.011 - DOI - PubMed
    1. Schmunis GA, Yadon ZE. Chagas disease: A Latin American health problem becoming a world health problem. Acta Trop. 2010;115(1–2):14–21. 10.1016/j.actatropica.2009.11.003 - DOI - PubMed
    1. Jannin J, Villa L. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz. 2007;102(Suppl. I):95–97. 10.1590/S0074-02762007005000106 - DOI - PubMed
    1. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic chagas disease with benznidazole versus no treatment: A nonrandomized trial. Ann Intern Med. 2006;144(10):724–734. 144/10/724 [pii] 10.7326/0003-4819-144-10-200605160-00006 - DOI - PubMed
    1. Rocha MOC, Ribeiro AL, Viotti R, et al. A Risk Score for Predicting Death in Chagas’ Heart Disease. N Engl J Med. 2006;355(23):2488–2491. 10.1056/NEJMc062580 - DOI - PubMed

Publication types

Associated data